In the study, 31 patients with type 2 Diabetes received single subcutaneous injections of IcoSema, icodec, or semaglutide, with 69 weeks washout between doses
Too dilute and you are injecting unnecessarily large volumes
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used mainly in treating type 2 diabetes, is the subject of increasing interest in scientific research due to its promising applications in treating various pathological conditions and those mentioned above
By integrating this medication with personalized coaching, nutrition guidance, and tailored fitness plans, Minimal empowers you to reach your health goals sustainably
For a full breakdown, see our guide to retatrutide side effects